Side-by-side comparison of mechanisms, dosing, interactions, and stacking potential.
| BPC-157 (Oral Stable Form) | TB-500 (Thymosin Beta-4) | |
|---|---|---|
| Category | Peptides | Peptides |
| Standard Dose | Research indicates 250-500 mcg twice daily via oral capsule on empty stomach. | Research indicates 2-2.5 mg administered twice weekly via subcutaneous injection. |
| Timing | On empty stomach, 30 minutes before meals. Twice daily dosing (morning and evening) provides consistent levels. | No strict timing requirements. Can be administered at any time of day. Systemic action means injection location is not critical. |
| Cycle Duration | 4-12 weeks. Oral form enables easier long-term use compared to injectable. | Loading phase: 4-6 weeks. Total cycle: 8-16 weeks. |
| Evidence Level | animal_plus_anecdotal | animal_plus_anecdotal |
Oral-stable BPC-157, typically formulated as the arginate salt, retains the same mechanism as standard BPC-157 — promoting angiogenesis via VEGFR2/PI3K/Akt/eNOS and Src-Caveolin-1-eNOS pathways, enhancing nitric oxide production, and stimulating tendon fibroblast growth and collagen formation. The arginate salt provides a protective buffer against gastric acid degradation, maintaining peptide integrity across a wider pH range. BPC-157 demonstrates remarkable native stability in human gastric juice (24+ hours), and the arginate form reportedly achieves 7-fold greater oral bioavailability compared to the acetate salt in preclinical studies.
Research indicates 250-500 mcg twice daily via oral capsule on empty stomach.
On empty stomach, 30 minutes before meals. Twice daily dosing (morning and evening) provides consistent levels.
4-12 weeks. Oral form enables easier long-term use compared to injectable.
TB-500 is a synthetic fragment of Thymosin Beta-4, a 43-amino acid protein that sequesters G-actin monomers, preventing premature polymerization and facilitating cellular migration and morphological changes essential for wound healing. It upregulates actin to promote cell migration, proliferation, and differentiation of stem/progenitor cells at injury sites. TB-500 also enhances angiogenesis, reduces inflammation, and promotes tissue remodeling through increased re-epithelialization and vascular density.
Research indicates 2-2.5 mg administered twice weekly via subcutaneous injection.
No strict timing requirements. Can be administered at any time of day. Systemic action means injection location is not critical.
Loading phase: 4-6 weeks. Total cycle: 8-16 weeks.
Take our free assessment to get personalized recommendations based on your health goals, current stack, and biomarkers.
Get Your Free Protocol →or take the assessment →